

Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci

David Ellinghaus,¹ Eva Ellinghaus,¹ Rajan P. Nair,² Philip E. Stuart,² Tõnu Esko,^{3,4} Andres Metspalu,^{3,4} Sophie Debrus,⁵ John V. Raelson,⁶ Trilokraj Tejasvi,² Majid Belouchi,⁷ Sarah L. West,⁸ Jonathan N. Barker,⁸ Sulev Kõks,⁹ Külli Kingo,¹⁰ Tobias Balschun,¹ Orazio Palmieri,¹¹ Vito Annese,^{11,12} Christian Gieger,¹³ H. Erich Wichmann,^{14,15,16} Michael Kabesch,¹⁷ Richard C. Trembath,⁸ Christopher G. Mathew,⁸ Gonçalo R. Abecasis,¹⁸ Stephan Weidinger,¹⁹ Susanna Nikolaus,^{20,21} Stefan Schreiber,^{1,21} James T. Elder,^{2,22} Michael Weichenthal,¹⁹ Michael Nothnagel,^{23,24} and Andre Franke^{1,24,*}

Psoriasis (PS) and Crohn disease (CD) have been shown to be epidemiologically, pathologically, and therapeutically connected, but little is known about their shared genetic causes. We performed meta-analyses of five published genome-wide association studies on PS (2,529 cases and 4,955 controls) and CD (2,142 cases and 5,505 controls), followed up 20 loci that showed strongest evidence for shared disease association and, furthermore, tested cross-disease associations for previously reported PS and CD risk alleles in additional 6,115 PS cases, 4,073 CD cases, and 10,100 controls. We identified seven susceptibility loci outside the human leukocyte antigen region (9p24 near *JAK2*, 10q22 at *ZMIZ1*, 11q13 near *PRDX5*, 16p13 near *SOCS1*, 17q21 at *STAT3*, 19p13 near *FUT2*, and 22q11 at *YDJC*) shared between PS and CD with genome-wide significance ($p < 5 \times 10^{-8}$) and confirmed four already established PS and CD risk loci (*IL23R*, *IL12B*, *REL*, and *TYK2*). Three of the shared loci are also genome-wide significantly associated with PS alone (10q22 at *ZMIZ1*, $p_{rs1250544} = 3.53 \times 10^{-8}$, 11q13 near *PRDX5*, $p_{rs694739} = 3.71 \times 10^{-9}$, 22q11 at *YDJC*, $p_{rs181359} = 8.02 \times 10^{-10}$). In addition, we identified one susceptibility locus for CD (16p13 near *SOCS1*, $p_{rs4780355} = 4.99 \times 10^{-8}$). Refinement of association signals identified shared genome-wide significant associations for exonic SNPs at 10q22 (*ZMIZ1*) and in silico expression quantitative trait locus analyses revealed that the associations at *ZMIZ1* and near *SOCS1* have a potential functional effect on gene expression. Our results show the usefulness of joint analyses of clinically distinct immune-mediated diseases and enlarge the map of shared genetic risk loci.

Introduction

Psoriasis (PS [MIM 177900]) and Crohn disease (CD [MIM 266600]) are both chronic inflammatory epithelial disorders that are triggered by an activated cellular immune system and have an estimated sibling relative risk (λ_s) of 4–11^{1,2} and 25–42,³ respectively, and a prevalence of 2%–3% and about 0.1%, respectively, in populations of European ancestry.^{4,5} PS is a common hyperproliferative disorder of the skin, characterized by red scaly plaques, typically occurring on the elbows, knees, scalp, and lower back.⁶ In contrast, CD is primarily a gut disorder affecting any aspect of the gastrointestinal tract but with extraintestinal manifestations which might also affect the skin (e.g., erythema nodosum and pyoderma gangraenosum).⁷ It results from the interac-

tion of environmental factors, including the commensal microflora, with host immune mechanisms in a genetically susceptible host.⁸ Although PS and CD are clinically distinct diseases, they are observed together more frequently than expected by chance, which could indicate shared genetic factors acting in the etiology of both diseases.^{9–11} Recently, several genome-wide association studies (GWASs) have successfully been carried out separately for CD and PS^{12–20} and identified shared susceptibility genes, such as *IL23R* (MIM 607562), *IL12B* (MIM 161561), *REL* (MIM 164910), and *TYK2* (MIM 176941), thereby providing further evidence for a genetic overlap of both diseases.^{13,16,21–23} One of the best characterized risk loci for both CD and PS is *IL23R*, located in a drug-targetable pathway.²⁴ IL-23, a pro-inflammatory cytokine, is

¹Institute of Clinical Molecular Biology, Christian-Albrechts-University, 24105 Kiel, Germany; ²Department of Dermatology, University of Michigan, Ann Arbor, MI 48109, USA; ³Estonian Genome Center, University of Tartu, 50409 Tartu, Estonia; ⁴Institute of Molecular and Cell Biology, University of Tartu, 50409 Tartu, Estonia; ⁵Gatineau, QC J9J 2X6, Canada; ⁶PGX-Services, Montreal, QC H2T 1S1, Canada; ⁷Genizon BioSciences, Inc., St. Laurent, QC H4T 2C7, Canada; ⁸Division of Genetics and Molecular Medicine, King's College London, London SE1 9RT, UK; ⁹Department of Physiology, Centre of Translational Medicine and Centre of Translational Genomics, University of Tartu, 50409 Tartu, Estonia; ¹⁰Department of Dermatology and Venerology, University of Tartu, 50409 Tartu, Estonia; ¹¹Division of Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico-Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo 71013, Italy; ¹²Unit of Gastroenterology SOD2, Azienda Ospedaliero Universitaria Careggi, Florence 50134, Italy; ¹³Institute of Genetic Epidemiology, Helmholtz Centre Munich, German Research Center for Environmental Health, 85764 Neuherberg, Germany; ¹⁴Institute of Epidemiology I, Helmholtz Centre Munich, German Research Center for Environmental Health, 85764 Neuherberg, Germany; ¹⁵Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-University, 81377 Munich, Germany; ¹⁶Klinikum Grosshadern, 81377 Munich, Germany; ¹⁷Department of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, 30625 Hannover, Germany; ¹⁸Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109, USA; ¹⁹Department of Dermatology, Allergology, and Venerology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, 24105 Kiel, Germany; ²⁰PopGen Biobank, Christian-Albrechts-University Kiel, 24105 Kiel, Germany; ²¹Department of General Internal Medicine, University Hospital Schleswig-Holstein, 24105 Kiel, Germany; ²²Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI 48105, USA; ²³Institute of Medical Informatics and Statistics, Christian-Albrechts University, 24105 Kiel, Germany

²⁴These authors contributed equally to this work

*Correspondence: a.franke@mucosa.de

DOI 10.1016/j.ajhg.2012.02.020. ©2012 by The American Society of Human Genetics. All rights reserved.




Figure 1. Study Design for the Combined Analysis of CD and PS

For discovery, we conducted a PS and a CD GWAS meta-analysis (panel A and B in Table S1), respectively, and employed two strategies (*OVERLAP* and *COMBINED*) to systematically search for shared risk loci. In a first approach (*OVERLAP*), we tested established non-HLA PS risk SNPs for potential association ($p < 0.01$) with CD and vice versa. In a second approach (*COMBINED*), we selected SNPs from 20 loci for being nominally associated in each of the single-disease meta-analyses ($p_{\text{panel A}} < 0.05$, $p_{\text{panel B}} < 0.05$) and for being significantly associated in the combined-phenotype association analysis at the 10^{-4} level ($p_{\text{panel A\&B}} < 10^{-4}$). For replication, follow-up SNP genotyping was performed for CD and PS in independent replication panels (panels C–E in Table S1). The following abbreviations are used: PS-GER, German PS GWAS; PS-US, United States PS GWAS; PS-Canada, Canadian PS GWAS; CD-GER, German CD GWAS; and CD-UK, United Kingdom CD GWAS. For each panel, numbers of cases/controls are displayed in parentheses.

thought to be a key player driving autoimmunity in human disease.²⁵ A recent functional characterization of the amino acid substitution R381Q in *IL23R* suggests that IL-23-induced Th17 cell effector function is reduced in protective allele carriers and leads to protection against several autoimmune diseases, including PS, CD, and ankylosing spondylitis.²⁶

So far, shared susceptibility loci for CD and PS have been identified by single-disease GWAS for CD or PS separately, and established risk SNPs for one disease are usually tested for association in another disease,^{27–31} rather than in a combined systematic approach. Combined GWASs were only conducted across clinically related phenotypes, such as CD and ulcerative colitis (UC),³² CD and sarcoidosis (SA)²⁷ or CD and celiac disease (CeID).³³ Recently, Zhernakova et al.³⁴ performed a meta-analysis with a similar systematic approach that combined genome-wide genotype data from two autoimmune diseases affecting different organs, namely CeID and rheumatoid arthritis (RA). They identified eight shared risk loci outside the human leukocyte antigen (HLA) region for CeID and RA, four of them previously not known to be associated with either CeID or RA. Based on genome-wide SNP data for CeID and RA, the authors identified an increased probability for CeID risk SNPs to confer also an increase in risk for RA and vice versa. Zhernakova et al.³⁴ postulated criteria for declaring a SNP as being a shared risk factor for two clinically distinct diseases, namely that shared SNPs (1) have to reach genome-wide significance in the combined analysis of the initial GWAS screening stage and the replication stage of the two distinct diseases ($p_{\text{GWAS+Repl}} < 5 \times 10^{-8}$) and (2) have to achieve, for each disease separately, nominal significance in the replication stage ($p_{\text{Repl}} < 0.05$) as well as $p_{\text{GWAS+Repl}} < 10^{-3}$ in the combined analysis of screening and replication stage.

We used the criteria proposed by Zhernakova et al.³⁴ in a genome-wide association analysis combining CD and PS to systematically identify shared risk loci associated with both diseases. A two-fold strategy was employed: in a first approach (*OVERLAP*), we tested established non-HLA CD risk SNPs for association with PS and vice versa, thereby seeking confirmation of whether known risk loci for one disease also play a role in the etiology of the other disease, disregarding the direction of effect. In a second approach (*COMBINED*), we performed a meta-analysis for the combined phenotype based on genome-wide data sets of both CD and PS in order to increase power for the detection of new shared risk alleles because of an increased sample size. The latter approach allows consideration of same-direction as well as opposing-direction allelic effects of putative shared markers between CD and PS through the use of suitable allele coding. We followed up 20 loci that showed the strongest association in the *COMBINED* approach and that had not been previously reported as being risk factors for either CD or PS. Follow-up was performed in independent replication panels from Germany, Estonia, Italy, United Kingdom, and the United States (see Table S1, available online).

Subjects and Methods

Study Subjects

We analyzed a collection of different data sets. Figure 1 details the different panels and their use in this study. For discovery, we combined genome-wide case-control data of single-nucleotide polymorphisms (SNP) for psoriasis (PS; panel A) and Crohn disease (CD; panel B) (see Table S1) respectively, conducted genome-wide meta-analyses on PS and CD, respectively, and employed two strategies (*COMBINED* and *OVERLAP*, see below) to systematically identify risk loci associated with both diseases. Replication was

performed in independent replication panels from Germany (see panels C–E), Estonia (panels C and D), Italy (panel E), United Kingdom (panels C and E), and the United States (panel C) (see Table S1). Written, informed consent was obtained from all study participants and all protocols were approved by the institutional ethical review committees of the participating centers.

Initial GWAS and German Replication Data

All German CD patients in discovery and replication panels (B and C–E, respectively) were recruited either at the Department of General Internal Medicine, Christian-Albrechts-University, Kiel, and the Charité University Hospital, Berlin; through local outpatient services; or nationwide with the support of the German Crohn and Colitis Foundation. German PS cases in discovery and replication panels (A and C and D, respectively) were recruited either at the Department of Dermatology, Christian-Albrechts-University, Kiel, or the Department of Dermatology and Allergy, Technical University, Munich, or through local outpatient services. Individuals were considered to be affected by PS if chronic plaque or guttate psoriasis lesions covered more than 1% of the total body surface area or if at least two skin, scalp, nail, or joint lesions were clinically diagnosed as psoriasis. The 4,680 German healthy control individuals in discovery and replication panels (A–E) were obtained from the Popgen biobank.³⁵ The additional 3,391 German healthy controls (after quality control measures) in the discovery panels (A and B) were selected from the KORA S3+S4 survey, an independent population-based sample from the general population living in the region of Augsburg, southern Germany.³⁶ Another 674 German healthy controls in the discovery panels (A and B) were selected from ISAAC Phase II study.³⁷ German GWAS controls of the discovery phase were randomly assigned to panels A and B at equal proportions, while ensuring that controls in panel A did not overlap with German GWAS controls used in the independent genome-wide meta-analysis on CD.¹³ The Collaborative Association Study of Psoriasis (CASP) samples¹⁴ consisted of 1,303 PS cases and 1,322 controls after quality control measures and are part of panel A in our study. The data sets used for the analyses described in this manuscript were obtained from the database of Genotype and Phenotype (dbGaP). The genotyping of samples was provided through the Genetic Association Information Network (GAIN).³⁸ The Canadian samples (from Genizon BioSciences and M. Belouchi, unpublished data) consisted of 757 PS cases and 987 controls sampled from the Québec founder population (QFP) after quality control measures. They are part of panel A. Membership in the QFP was defined as having four grandparents with French-Canadian family names who were born in the Province of Québec, Canada, or in adjacent areas in the provinces of New Brunswick and Ontario or in New England or New York state. This criterion assured that all subjects were descendants of French-Canadians living before the 1960s, after which time admixture with non-French-Canadians became more common. CD cases and controls from the United Kingdom were recruited from the 1958 birth cohort and UK National Blood Service for the Wellcome Trust Case Controls Consortium (WTCCC) (described in details in WTCCC²⁸). The WTCCC1 CD samples consisted of 1,662 CD cases and 2,860 healthy controls after quality control procedures and entered the analysis as part of panel B.

Additional Replication Data

A number of collaborative data sets were used as replication panels. The Estonian samples used in the *OVERLAP* and *COMBINED* approaches (part of panels C and D) were collected at the Department of Dermatology and Venerology and at the Department of

Physiology and Centre of Translational Medicine at the University of Tartu.

Additional Estonian samples (part of panel C) used for replication in the *OVERLAP* approach consisted of samples provided by the population-based biobank of the Estonian Genome Center, University of Tartu. Subjects were recruited by general practitioners (GP) and physicians in the hospitals. Participants in the hospitals were randomly selected from individuals visiting GP offices or hospitals. Diagnosis of PS on the basis of clinical symptoms was posed by a general practitioner and confirmed by a dermatologist. At the moment of recruitment, the controls did not report diagnosis of osteoarthritis, psoriasis, or autoimmune diseases. The United States samples (part of panel C) used for replication in the *OVERLAP* approach consisted of 2,137 PS cases and 1,903 controls of white European ancestry from the United States. The Italian samples (panel E) used in the *COMBINED* approach consisted of 688 CD cases and 879 healthy controls that were used in the independent genome-wide meta-analysis on CD.¹³ The psoriasis data set from the United Kingdom consisted of 2,178 PS cases collected through the Genetic Analysis of Psoriasis Consortium (GAPC) and 2,657 controls from the WTCCC2 common control set, used as the GWAS discovery set described in Strange et al. in 2010.¹⁶ Only controls that did not overlap with WTCCC1 controls were used. UK cases and controls entered the analysis as part of panel C and E.

Quality Control and Genome-wide Genotype Imputation

Quality control (QC) was performed for each sample set separately. In each sample set samples with more than 5% missing data were excluded before genotype imputation. We also excluded individuals from each pair of unexpected duplicates or relatives, as well as outlier individuals with average marker heterozygosities of ± 5 standard deviation away from the sample mean. The remaining samples were tested for population stratification with the principal components stratification method as implemented in EIGENSTRAT,³⁹ and population outliers were subsequently excluded. SNPs that had more than 5% missing data, a minor allele frequency less than 1% or deviated from Hardy-Weinberg equilibrium (exact $p < 10^{-4}$ in controls) per sample set were excluded with the PLINK software version 1.07.⁴⁰ SNP imputation was carried out with the BEAGLE v.3.1.1⁴¹ software package and 690 HapMap3 reference haplotypes from the CEU, TSI, MEX, and GIH cohorts⁴² to predict missing autosomal genotypes in silico. We subsequently analyzed only those SNPs that could be imputed with moderate confidence (INFO score $r^2 > 0.3$) and had a minor allele frequency more than 1% in cases or in controls. To take imputation uncertainty into account, phenotypic association was tested for allele dosage data separately for each of the five GWAS data sets in panels A and B through the use of PLINK's logistic regression framework for dosage data. To control potentially confounding effects due to population stratification, we adjusted for the top ten eigenvectors from EIGENSTRAT in the regression analysis. The genomic inflation factor λ is defined as the ratio of the medians of the sample χ^2 test statistics and the 1 degree of freedom χ^2 distribution (0.455).⁴³ Because the estimated genomic inflation factor λ scales with sample size, it is informative to report the inflation factor for an equivalent study of 1,000 cases and 1,000 controls (λ_{1000}) by rescaling λ .⁴⁴

Meta-Analyses

Meta-analyses were performed with PLINK's meta-analysis function and with its standard error of odds ratio weighting option

(inverse variance weighting), which implicitly deals with imputation uncertainty. For the combined-phenotype analysis, we performed two sorts of meta-analysis in order to detect associations of SNPs with either the same or opposite allelic effects in the two diseases. For the same-effect analysis, the meta-analysis was carried out as usual. For the opposite-effect analysis, first we flipped minor and major alleles of each biallelic SNP in the CD data sets to mimic an opposite-direction effect of the allele in CD and performed a meta-analysis afterward. For both effects models, we considered only those SNPs whose genotypes were available from at least four out of the five GWAS data sets in panels A and B.

Follow-Up Genotyping

Genotyping was carried out with our Sequenom iPLEX platform from Sequenom and TaqMan technology from Applied Biosystems. Individuals with more than 3% missing data were removed. SNPs that had more than 3% missing data, a minor allele frequency less than 1% or deviated from Hardy-Weinberg equilibrium (exact $p < 10^{-4}$ in controls) per sample set were excluded. p values for allele-based tests of phenotypic association for each single-replication sample sets (panels C–E) were calculated with PLINK. PLINK's meta-analysis function was used to obtain p values for the replication data set (p_{Rep}) and for the combined discovery-replication data set ($p_{\text{GWAS+Rep}}$).

Regional Imputation Based on the 1000 Genomes Project Reference

To enable imputation based on the 1000 Genomes project data, SNP positions referring to NCBI build 36 were mapped to build 37. SNP imputation was carried out with the BEAGLE software package v.3.1.1⁴¹ and 566 EUR (European) haplotypes generated by the 1000 Genomes Project.⁴⁵ We analyzed only imputed SNPs with moderate imputation confidence (INFO score $r^2 > 0.3$) and a minor allele frequency more than 1% in cases or in controls.

Gene Relationships across Implicated Loci Pathway Analysis

The Gene Relationships Across Implicated Loci (GRAIL) software⁴⁶ quantifies functional similarity between genes by applying established statistical text mining methods to the PubMed database of published scientific abstracts. As input we used the following list of SNPs: rs2201841, rs2082412, rs702873, rs12720356, rs10758669, rs694739, rs281379, rs181359, rs4780355, rs744166, and rs1250544. GRAIL was run with the following settings: HapMap release = HapMap release 22/hg18; HapMap population = CEU (Utah residents with ancestry from northern and western Europe from the Centre d'Étude du Polymorphisme Humain collection); functional data source = PubMed Text (April 2011); and gene size correction = on. GRAIL output results were visualized with VIZ-GRAIL.

Results

Preparation of Single-Disease Meta-Analyses for Discovery Phase by Means of HapMap3 Imputation

The overall study workflow for the combined analysis of CD and PS is displayed in Figure 1. For discovery, we conducted a meta-analysis on PS comprising 2,529 PS cases and 4,955 controls from three previously published GWASs,^{14,15} all of European descent (panel A in Table

S1). SNP data were combined with genotype imputation based on the HapMap3 reference. We subsequently used standard meta-analysis methodology (see **Subjects and Methods**). In total, 1,121,166 quality-controlled autosomal-imputed SNP markers were available for the analysis on PS. To control for potential population stratification, we adjusted association test statistics by means of principal component analysis (PCA) (see **Subjects and Methods**). A quantile-quantile (Q-Q) plot of the meta-analysis revealed a marked excess of significant associations in the tail of the distribution (Figure S1A), which is primarily due to thousands of highly significant association signals from the HLA region. Genetic heterogeneity was low; there was an estimated genomic inflation factor of $\lambda_{1000} = 1.027^{43,44}$ (see **Subjects and Methods**). Results of the meta-analysis on PS are summarized in Figure S2A.

In the same way, we performed a meta-analysis on CD by using 1,034,639 quality-controlled autosomal-imputed markers from a German GWAS¹³ and a previously published UK GWAS,²⁸ consisting of 2,142 CD cases and 5,505 controls in total (panel B in Table S1). Again, we observed low genomic inflation ($\lambda_{1000} = 1.032$, Figure S1B). Results of the meta-analysis on CD are summarized in Figure S2B.

OVERLAP Approach: Cross-Disease Analysis of Established Risk SNPs

So far, four established GWAS risk loci that are located outside the HLA region and shared between CD and PS have been reported in the literature, namely *IL23R*, *IL12B*, *REL*, and *TYK2* (Table 1). Although the markers that showed the strongest association differed between the two diseases at each of the first three loci, we found the same SNP rs12720356 at *TYK2* to be associated with both CD and PS. To seek confirmation of whether known risk loci for CD also play a role in the etiology of PS and vice versa, we checked whether markers that were significant ($p < 0.01$) in our PS meta-analysis were among the 71 established risk SNPs previously implicated in CD¹³ and whether significant markers ($p < 0.01$) from our CD meta-analysis were among the 25 established PS risk SNPs.^{14–20} The four already established shared risk SNPs (Table 1) were excluded. Given the well-established and heterogeneous allelic associations of the HLA region on chromosome 6 with both CD and PS, we also excluded all markers from the extended HLA region (chr6:25–34 Mb). Although none of the known PS SNPs were significantly associated with CD in our analysis, five out of the 71 known CD risk SNPs met our criterion of significance, namely rs10758669 (*JAK2* [MIM 147796]), rs694739 (*PRDX5* [MIM 606583]), rs281379 (*FUT2* [MIM 182100]), rs744166 (*STAT3* [MIM 102582]), and rs181359 (*YDJC*;HGNC 27158). We genotyped these five SNPs by using TaqMan technology in a large independent replication panel comprising 3,937 PS cases and 4,847 controls but also used summary statistics data of the five SNPs from an independent GWAS on PS¹⁶ comprising 2,178 PS cases and 2,657 controls. The overall replication panel consisted of 6,115 PS cases and 7,504

Table 1. Established Risk Loci Shared between CD and PS from Published Studies on CD and PS, Respectively

Locus	Genes of Interest ^a	Top CD dbSNP ID ^b	Risk Allele	OR	Top PS dbSNP ID ^b	Risk Allele	OR	LD between CD and PS SNPs (D'/r ²)	Comment
1p31	<i>IL23R</i>	rs11209026 ^c	G	2.66	rs2201841 ^f	G	1.13	1.0/0.018	different markers
5q33	<i>IL12B</i>	rs6556412 ^d	A	1.18	rs2082412 ^f	G	1.44	0.715/0.269	different markers
2p16	<i>REL</i>	rs10181042 ^e	T	1.14	rs702873 ^g	G	1.12	0.036/0.001	different markers
19p13	<i>TYK2</i>	rs12720356 ^e	G	1.12	rs12720356 ^g	T	1.40	same marker	same marker, opposite direction of effect

^aCandidate genes of interest are listed for the locus.

^bLead SNP with most significant association within a locus, as stated in the reference publication.

^cSee Franke et al.¹³ and Duerr et al.²¹

^dSee Barrett et al.¹² and Franke et al.¹³

^eSee Franke et al.¹³

^fSee Cargill et al.²² and Nair et al.²³

^gSee Strange et al.¹⁶

controls (panel C, Table S1). We performed single-marker association tests for panel C ($p_{\text{PS-Rep1}}$) and conducted a meta-analysis ($p_{\text{PS-GWAS+Rep1}}$) by combining association results from the GWAS ($p_{\text{PS-GWAS}}$) and the replication ($p_{\text{PS-Rep1}}$) stages (Table 2). All of the CD risk SNPs were also significantly associated with PS at the previously proposed level³⁴ of $p_{\text{PS-Rep1}} < 0.05$ and $p_{\text{PS-GWAS+Rep1}} < 10^{-3}$ (rs10758669 near *JAK2*, rs694739 near *PRDX5*, rs281379 near *FUT2*, and rs181359 at *YDJC*, rs744166 at *STAT3*). These five SNPs have already been reported to show significant association at the genome-wide level ($p_{\text{CD-GWAS+Rep1}} < 5 \times 10^{-8}$, $p_{\text{CD-Rep1}} < 0.05$, and $p_{\text{CD-GWAS+Rep1}} < 10^{-3}$) in a very large, independent genome-wide meta-analysis on CD roughly three times the size of this one, that is comprising 6,333 CD cases and 15,056 controls.¹³ All five SNPs achieved genome-wide significance in the combined analysis of PS discovery panel A, PS replication panel C, and CD discovery data from Franke et al.¹³ ($p_{\text{CDPS-GWAS+Rep1}} < 5 \times 10^{-8}$). Furthermore, SNP rs694739, 7.9 kb downstream of *PRDX5*, as well as SNP rs181359, 53.7 kb downstream of *YDJC*, reached genome-wide significance for PS only ($p_{\text{rs694739}} = 3.71 \times 10^{-9}$ and $p_{\text{rs181359}} = 8.02 \times 10^{-10}$). We also observed a highly significant association at the *FUT2* locus ($p_{\text{rs281379}} = 7.86 \times 10^{-8}$) for PS only.

COMBINED Approach, Part 1: Meta-Analysis Considering Same-Direction Effects

In order to identify additional shared genetic susceptibility loci in CD and PS, we performed a meta-analysis of the combined phenotype where CD and PS were considered as a single phenotype. The disease-specific meta-analyses (panels A and B) were merged to form a combined-phenotype meta-analysis discovery panel comprising 2,142 CD cases, 2,529 PS cases, and 10,460 healthy controls. In total, 1,123,777 quality-controlled autosomal markers were available for the analysis in at least four out of the five GWAS data sets. As with the *OVERLAP* approach, we excluded all markers from the extended HLA region (chr6:25-34Mb), leaving 1,116,213 autosomal SNPs for screening of shared risk loci. We observed only low

genomic inflation for the same-direction meta-analysis ($\lambda_{1000} = 1.023$; Figure S3A). After exclusion of established loci for PS and CD, the inflation factors further decreased (Figure S3C). To provide proof of principle for our approach, we first examined association signals at the three established shared risk loci with same-direction effects of alleles for CD and PS (see Table 1). We observed highly significant association signals for all three loci ($p_{\text{IL23R}} = 1.82 \times 10^{-22}$, $p_{\text{IL12B}} = 3.32 \times 10^{-7}$, and $p_{\text{REL}} = 1.53 \times 10^{-7}$; Figures S4A–S4C). Subsequently, we selected SNPs for being nominally associated in each of the single-disease meta-analyses ($p_{\text{CD-GWAS}} < 0.05$, $p_{\text{PS-GWAS}} < 0.05$) and for being significantly associated in the combined-phenotype association analysis at the 10^{-4} level ($p_{\text{CDPS-GWAS}} < 1 \times 10^{-4}$). This resulted in 17 SNPs located at 17 distinct loci. Except for the four known shared loci (see Table 1), we did not exclude established risk loci from either CD or PS to maintain the chance of detecting shared risk alleles at these loci. Because one of the 17 SNPs is located at 10q22 (*ZMIZ1* [MIM 607159]), which is an established CD risk locus, we added the established CD-associated SNP rs1250550 from this region to the list of follow-up SNPs. We then genotyped these 18 SNPs in an independent panel of 1,713 CD cases, 1,009 PS cases and 3,565 controls (panel D, Table S1D) by using the Sequenom iPLEX platform. Association results for all 18 SNPs are shown in Table S2. The strongest association was observed at *ZMIZ1* for SNP rs1250544 ($p_{\text{CDPS-GWAS}} = 1.12 \times 10^{-5}$ and $p_{\text{CDPS-GWAS+Rep1}} = 2.66 \times 10^{-10}$; see Table S2 and Figure S5A) and yielded genome-wide significance in the same-effect combined-phenotype analysis of discovery panels A and B and replication panel D. SNP rs1250544 reached also genome-wide significance for PS alone ($p_{\text{PS-GWAS+Rep1}} = 3.90 \times 10^{-8}$). A robust association with CD, but not with PS, was observed at *SOCS1* (MIM 603597) on chromosomal region 16p13 ($p_{\text{CDPS-GWAS}} = 9.36 \times 10^{-7}$, $p_{\text{CD-GWAS}} = 1.47 \times 10^{-3}$, and $p_{\text{CD-GWAS+Rep1}} = 1.01 \times 10^{-7}$ for rs4780355; see Table S2 and Figure S5B). We further corroborated both association signals by genotyping SNPs rs1250544 and rs4780355 in additional sample sets from Germany and Italy, comprising 2,360 CD cases and 1,015 healthy controls, but we also

Table 2. Association Results of OVERLAP Approach from Cross-Disease Comparison of Established Risk Markers

Chr	SNP	A1	Locus	CD GWAS Meta-Analysis ^a (6,333/15,056)			PS GWAS (2,529/4,955)			PS Replication (6,115/7,504)			PS GWAS and Repl (8,644/12,459)			CD GWAS Meta-Analysis ^a + PS GWAS and Repl (14,977/27,515)			Status Now ^b
				OR	P	P	OR	P	OR	P	OR	P	OR	P	OR	P			
9	rs10758669	C	JAK2	1.18	1.0 × 10 ⁻¹³	2.43 × 10 ⁻⁰³	1.13	2.47 × 10 ⁻⁰³	1.08	2.69 × 10 ⁻⁰⁵	1.10	1.30 × 10 ⁻¹⁶	1.14	CD-PS, CD					
11	rs694739	G	PRDX5	0.89	3.4 × 10 ⁻⁰⁷	1.13 × 10 ⁻⁰⁴	0.86	6.12 × 10 ⁻⁰⁶	0.89	3.71 × 10 ⁻⁰⁹	0.88	2.41 × 10 ⁻¹⁴	0.89	PS, CD-PS, CD					
19	rs281379	A	FUT2	1.13	8.6 × 10 ⁻¹⁰	3.22 × 10 ⁻⁰³	1.13	7.12 × 10 ⁻⁰⁶	1.13	7.86 × 10 ⁻⁰⁸	1.12	1.32 × 10 ⁻¹⁷	1.13	CD-PS, CD					
22	rs181359	G	YDJC	0.83	6.3 × 10 ⁻¹³	4.83 × 10 ⁻⁰³	0.88	3.54 × 10 ⁻⁰⁸	0.84	8.02 × 10 ⁻¹⁰	0.85	1.33 × 10 ⁻²¹	0.84	PS, CD-PS, CD					
17	rs744166 ^c	A	STAT3	1.13	1.1 × 10 ⁻⁰⁷	2.44 × 10 ⁻⁰⁴	0.87	1.49 × 10 ⁻⁰²	0.94	5.30 × 10 ⁻⁰⁵	0.92	5.48 × 10 ⁻¹¹	0.90	CD-PS, CD					

The following abbreviations are used: Chr, chromosome of marker; SNP, rs ID; A1, minor allele; Locus, one candidate gene in the region; p/OR, p value and corresponding odds ratio with respect to minor allele for the large GWAS meta-analysis of CD.¹³ CD GWAS meta-analysis of PS (panel A), PS replication analysis (panel A), PS replication analysis (panel A) and PS replication (panel C), and combined analysis of CD GWAS meta-analysis¹³ and panels A and C. For each panel, numbers of cases/controls are displayed in parentheses.

^aSee Franke et al.¹³

^bStatus now: new status of association with CD and/or PS. All SNPs are established CD risk SNPs with $p < 5 \times 10^{-8}$ that were significant ($p < 0.01$) in our PS meta-analysis. All SNPs, except for rs744166, showed the same direction of effect for CD and PS. None of the SNPs showed an exact Hardy-Weinberg p value < 0.01 in the PS replication (panel C).

^cMinor and major alleles of rs744166 were flipped in the CD GWAS meta-analysis in order to calculate the combined-phenotype p value and odds ratio.

used summary statistics data of the two SNPs from the independent GWAS on PS¹⁶ comprising 2,178 PS cases and 2,657 controls (panel E in Table S1, the same cases and controls from the United Kingdom, as described in panel C). In the combined analysis of discovery panels A and B and replication panels D and E (Tables 3 and 4), SNP rs4780355 achieved genome-wide significance ($p_{\text{CDPS-GWAS+Repl}} = 1.37 \times 10^{-13}$) but also attained genome-wide significance for CD alone ($p_{\text{CD-GWAS+Repl}} = 4.99 \times 10^{-8}$).

COMBINED Approach, Part 2: Meta-Analysis Assuming Opposite-Direction Effects

An allele might confer a risk for CD while protecting against PS and vice versa, as is the case for *TYK2*. Therefore, we also screened our combined-phenotype meta-analysis data (panels A and B) while coding alleles in such a way as to consider the opposite effects of them in the two diseases (see Subjects and Methods). We observed low genomic inflation for the opposite-direction meta-analysis ($\lambda_{1000} = 1.009$, Figure S3B). After excluding established shared loci for PS and CD, the inflation factors further decreased (Figure S3D). In a first step, we checked the known risk SNP rs12720356 (*TYK2*; see Table 1) for opposite direction of effects. SNP rs12720356 had a p value of 4.09×10^{-5} in the combined analysis of panels A and B (Figure S4D); there was an odds ratio (OR) of 1.29 (95% confidence interval [CI] [1.10,1.51]) for allele A in panel A ($p_{\text{PS-GWAS}} = 1.39 \times 10^{-3}$) and of 0.78 (95% CI [0.65,0.94]) in panel B ($p_{\text{CD-GWAS}} = 1.01 \times 10^{-2}$). We then selected three SNPs for subsequent genotyping (with Sequenom) and testing in replication panel D (see Table S1D). The selection criteria were the same as for the same-direction effect meta-analysis. However, none of the three SNPs replicated in both diseases at p value < 0.05 (see Table S3).

In Silico Fine-Mapping: Refinement of Association Signals of COMBINED Approach

For refinement of the association signals at *ZMIZ1* and *SOCS1*, we imputed a region of about ± 1 Mb around the strongest signals from the discovery panels A and B (see Table S1) by using the EUR reference from the 1000 Genomes Project⁴⁵ (see Subjects and Methods). In silico fine-mapping of the region around *SOCS1* via standard meta-analysis methodology (see Subjects and Methods) confirmed rs4780355 to be highly significant in this region ($p_{\text{GWAS}} = 4.04 \times 10^{-7}$). Additionally, another SNP, rs2021511, which is located in the same intron as rs4780355 (2.9 kb downstream of rs4780355) showed the same magnitude of association ($p_{\text{GWAS}} = 1.58 \times 10^{-7}$; Figure 2) but was not selected for further replication because of the high linkage disequilibrium (LD) between SNPs rs4780355 and rs2021511 ($r^2 = 0.934$) according to the 1000 Genomes Project EUR reference. Screening of the imputed region of *SOCS1* for coding SNPs revealed one missense SNP with $p < 10^{-4}$ within the *TNP2* gene, namely rs11640138. We genotyped this SNP in replication

Table 3. Association Results of Combined-Phenotype Meta-Analysis Considering Same-Direction Effects of Alleles from COMBINED Approach

Chr	SNP	A1	Locus	CD+PS Discovery GWAS (4,671/10,460)		PS GWAS (2,529/4,955)		CD GWAS (2,142/5,505)		PS Replication (3,187/4,759)		CD Replication (4,073/2,478)	
				p	OR	p	OR	p	OR	p	OR	p	OR
10	rs1250544 ^a	G	ZMIZ1	1.12×10^{-05}	1.13	3.85×10^{-05}	1.18	3.31×10^{-02}	1.09	1.94×10^{-04}	1.14	5.28×10^{-07}	1.22
10	rs1250560 ^b	A	ZMIZ1	3.13×10^{-06}	0.87	4.31×10^{-06}	0.82	4.87×10^{-02}	0.92	1.06×10^{-03}	0.87	8.06×10^{-10}	0.79
10	rs1250559 ^b	A	ZMIZ1	1.53×10^{-07}	0.87	4.58×10^{-06}	0.82	3.46×10^{-02}	0.91	1.16×10^{-03}	0.87	4.10×10^{-10}	0.79
16	rs4780355 ^a	T	SOCS1	9.36×10^{-07}	1.16	1.72×10^{-04}	1.18	1.47×10^{-03}	1.15	7.53×10^{-04}	1.14	7.40×10^{-06}	1.19

The following abbreviations are used: Chr: chromosome of marker; SNP: rs ID; A1: minor allele; Locus: one candidate gene in the region; p/OR: p value and corresponding odds ratio with respect to minor allele for the combined-phenotype GWAS meta-analysis of CD and PS (panels A and B), GWAS meta-analysis of PS (panel A), GWAS meta-analysis of CD (panel B), PS replication analysis (as part of panel D), CD replication analysis (part of panel D, panel E). For each panel, numbers of cases/controls are displayed in parentheses. None of the SNPs showed an exact Hardy-Weinberg p value < 0.01 in the PS and CD replication panels (panels D and E).

^aSNPs were identified via genotype imputation based on the HapMap3 reference and P/OR are given according to that analysis.

^bSNPs were identified via genotype imputation based on the 1000 Genomes reference and P/OR are given according to that analysis.

panel D, but it did not replicate in either disease at p value < 0.05.

In silico fine-mapping of ZMIZ1 with the same methodology narrowed down the association signal to two coding SNPs, namely rs1250559 ($p_{CDPS-GWAS} = 1.53 \times 10^{-7}$, Figure 2) and rs1250560 ($p_{CDPS-GWAS} = 3.13 \times 10^{-6}$). According to the 1000 Genomes Project EUR reference, both SNPs are in near perfect LD ($r^2 = 0.948$). Depending on different splice variants of ZMIZ1, rs1250559 is either intronic or located in the 3-untranslated region (3-UTR), whereas rs1250560 is either an intronic SNP or a missense SNP located in exon 5. The intronic ZMIZ1 SNP rs1250544, which yielded the strongest signal from the initial same-effect combined-phenotype meta-analysis, and the missense SNP rs1250560 are 20.6 kb apart and in moderate LD ($r^2 = 0.682$). In order to substantiate our findings from the in silico analyses, we genotyped both ZMIZ1 SNPs in replication panels D and E (see Table S1). As shown in Tables 3 and 4, both SNPs were associated with PS at the 0.05 level and even showed genome-wide significance with CD ($p_{CD-Repl} = 8.06 \times 10^{-10}$ at rs1250560, $p_{CD-Repl} = 4.10 \times 10^{-10}$ at rs1250559). Interestingly, the association signals of these two SNPs were much stronger in the initial analysis of PS panel A than of CD panel B. The combined analysis of discovery panels A and B and replication panels

D and E yielded genome-wide significance for rs1250560 ($p_{CDPS-GWAS+Repl} = 7.34 \times 10^{-16}$) and rs1250559 ($p_{CDPS-GWAS+Repl} = 2.78 \times 10^{-16}$), both of which are of higher significance than was observed for rs1250544 ($p_{CDPS-GWAS+Repl} = 7.32 \times 10^{-14}$) (Tables 3 and 4).

Effect on Gene Expression

We subsequently assessed a potential functional effect of the four SNPs showing association for both CD and PS with the same direction of effects, namely rs1250544, rs1250559, rs1250560 (ZMIZ1), and rs4780355 (near SOCS1). To this end, we investigated the correlation of SNP genotypes with gene expression levels by means of in silico expression quantitative trait locus (eQTL) analysis by using the mRNABYSNPBROWSER software.⁴⁷ This program utilizes genotype data from 408,273 SNPs and gene expression data from Epstein-Barr-virus-transformed lymphoblastoid cell lines that were collected from 400 children and measured with the Affymetrix HG-U133 Plus 2.0 chip. Significant evidence (uncorrected $p_{Expression} < 10^{-4}$) for causing differential expression of ZMIZ1 was observed for SNP rs1250546 ($p_{rs1250546} = 8.10 \times 10^{-5}$), which is in high LD with our lead SNP rs1250544 ($r^2 = 0.829$). Also, we found an even stronger evidence for association between expression of C16ORF75 (MIM 612426), which is

Table 4. Association Results of Combined-Phenotype Meta-Analysis Considering Same-Direction Effects of Alleles from COMBINED Approach

Chr	SNP	A1	Locus	PS GWAS and Repl (5,716/9,714)		CD GWAS and Repl (6,215/7,983)		CD+PS GWAS and Repl (11,931/17,697)		Status Now
				p	OR	p	OR	p	OR	
10	rs1250544 ^a	G	ZMIZ1	3.53×10^{-08}	1.16	2.56×10^{-07}	1.16	7.32×10^{-14}	1.16	PS, CD-PS, CD
10	rs1250560 ^b	A	ZMIZ1	3.03×10^{-07}	0.84	4.10×10^{-09}	0.84	7.34×10^{-16}	0.85	CD-PS, CD
10	rs1250559 ^b	A	ZMIZ1	3.63×10^{-07}	0.84	1.24×10^{-09}	0.84	2.78×10^{-16}	0.85	CD-PS, CD
16	rs4780355 ^a	T	SOCS1	5.30×10^{-07}	1.15	4.99×10^{-08}	1.17	1.37×10^{-13}	1.16	CD-PS, CD

For abbreviations used, see Table 3. Combined analysis of PS GWAS meta-analysis (panel A) and PS replication (part of panel D), combined analysis of CD GWAS meta-analysis (panel B) and CD replication (part of panel D, panel E), combined analysis of CD+PS GWAS meta-analysis (panels A and B) and CD+PS replication (panels D and E).

^aSNPs were identified via genotype imputation based on the HapMap3 reference and p/OR are given according to that analysis.

^bSNPs were identified via genotype imputation based on the 1000 Genomes reference and p/OR are given according to that analysis.




Figure 2. Regional Association Plots of In Silico Fine-Mapping for Newly Detected Shared Risk Loci from COMBINED Approach
 Shared risk loci for CD and PS at (A) 10q22 (*ZMIZ1*) and (B) 16p13 (near *SOCS1*). eQTL analyses revealed a potential effect of the associations at *ZMIZ1* and near *SOCS1* on gene expression. p values ($-\log_{10}p$) are depicted with regard to the physical location of markers and are based on imputed genotypes. SNP genotypes were imputed with the EUR reference from 1000 Genomes Project⁴⁵ (see **Subjects and Methods**). The following abbreviations are used: blue-filled circle, lead SNP of the combined-phenotype data (panels A and B); other filled circles, analyzed SNPs of the combined-phenotype data (panels A and B) where the fill color corresponds to the strength of linkage disequilibrium (r^2) with the lead SNP (for color coding see legend in the upper right corner of each plot); green triangles, analyzed SNPs of the meta-analysis on PS (panel A); gray squares, analyzed SNPs of the meta-analysis on CD (panel B); and blue line, recombination intensity (cM/Mb). Positions and gene annotations are according to NCBI's build 37 (hg19).

STAT3, 22q11 at *YDJC*). These loci, except for *SOCS1*, were already known to play a role in CD etiology, but were of unknown significance for PS¹³ (see also **Table S5** for associations with other diseases). Notably, three of these loci showed genome-wide significance when tested for association with PS alone (10q22 at *ZMIZ1*, 11q13 near *PRDX5*, and 22q11 at *YDJC*). Furthermore, we revealed a risk locus for CD (16p13 near *SOCS1*). The identified shared risk loci point to functionally very interesting genes that might play a role in the pathogenesis of both CD and PS. The gene

located 90 kb upstream of *SOCS1*, and SNP rs243323 ($P_{rs243323} = 1.10 \times 10^{-8}$). This SNP is also in high LD with our lead SNP rs4780355 ($r^2 = 0.931$). Both proxy SNPs rs1250546 and rs243323 were also significantly associated in our same-effect combined-phenotype analysis of discovery panels A and B ($p_{G\text{WAS}} = 7.15 \times 10^{-5}$ for rs1250546, $p_{G\text{WAS}} = 1.80 \times 10^{-6}$ for rs243323). This in silico eQTL analysis supports the notion that our four reported SNPs might affect the expression of *ZMIZ1* and *C16ORF75*. The full list of significant associations between SNP genotypes and gene expression levels is shown in **Table S4**.

Discussion

In a large combined sample set of 6,215 CD cases, 8,644 PS cases and 20,560 healthy controls, we have identified seven non-HLA susceptibility loci shared between CD and PS (9p24 near *JAK2*, 10q22 at *ZMIZ1*, 11q13 near *PRDX5*, 16p13 near *SOCS1*, 19p13 near *FUT2*, 17q21 at

ZMIZ1 (also known as *hZIMP10* or *TRAFIP10*) encodes for the protein zinc finger MIZ type 1, which is a member of the protein inhibitor of activated STAT (PIAS) family. The protein regulates the activity of several transcription factors such as the androgen receptor, Smad3/4, and p53; regulates TGF- β /SMAD signaling; and is induced by retinoic acid.⁴⁸ *FUT2* encodes α -(1,2)fucosyltransferase (*FUT2*), a physiological trait that regulates expression of the Lewis human blood group of antigens on the surface of epithelial cells and in body fluids. Genetic variants in *FUT2* have been implicated in susceptibility to infections with Norovirus⁴⁹ and *Helicobacter pylori*.⁵⁰ *PRDX5* encodes Peroxiredoxin-5, which belongs to the peroxiredoxin family of antioxidant enzymes that reduce hydrogen peroxide and alkyl hydroperoxides and might play a protective role during inflammatory processes. *SOCS1* encodes the suppressor of cytokine signaling 1 (*SOCS1*), a protein that is member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling (*SOCS*) family. *SOCS1* is a cytokine-inducible negative




Figure 3. Gene Relationships across the 11 Shared Risk Loci of CD and PS Identified by GRAIL Analysis

GRAIL⁴⁶ is a statistical text-mining approach to quantify the degree of relatedness among genes in genomic disease regions. It estimates the statistical significance of the number of observed relationships with a null model in which relationships between the genes occur by random chance. A significance score p_{text} , which is adjusted for multiple hypothesis testing, represents the output GRAIL score. p_{text} values approximately estimate type-I error rates. Outer circle: lead SNPs from shared risk loci of both diseases; each box represents a SNP. Inner circle: genes of the genomic regions around lead SNPs that were identified based on LD properties; each box represents a gene; genes that were scored at $p_{\text{text}} < 0.05$ are significantly linked to genes in the other disease regions and are indicated in bold type. Lines: the lines between genes represent significant connections, with the thickness and redness of the lines being inversely proportional to the probability that a text-based connection would be seen by chance.

regulator of cytokine signaling.^{51,52} Cytokines such as IL2, IL3, erythropoietin, and interferon-gamma can induce expression of *SOCS1*.⁵³ Moreover, a potential functional effect of the associations at *ZMIZ1* and near *SOCS1* on gene expression was found by an in silico eQTL analysis.

The present study has increased the number of known shared CD and PS susceptibility loci to eleven (*IL12B*, *IL23R*, *REL*, *TYK2*, *JAK2*, *ZMIZ1*, *PRDX5*, *SOCS1*, *STAT3*, *FUT2*, and *YDJC*). To quantify the degree of relatedness between genes within the eleven loci, we used a published statistical genomics method, namely GRAIL (gene relationships across implicated loci),⁴⁶ that applies statistical text mining to PubMed abstracts (see **Subjects and Methods** and **Figure 3**). GRAIL highlights a number of nonrandom and evidence-based connections between the genes within the nine loci that might indicate overlap in the pathways acting in the etiology of CD and PS. Multiple genes (*IL12B*, *IL23R*, *TYK2*, *JAK2*, *SOCS1*, and *STAT3*) are

involved in IL23/Th17 signaling and play a critical role in the principal signaling mechanism for a wide array of cytokines and growth factors. It is noteworthy that genes *CDC37* ([MIM 605065] 21.7 kb downstream of the established shared risk locus at *TYK2*) and *STIP1* ([MIM 605063] 113.5 kb upstream of the identified shared risk at *PRDX5*) were found by GRAIL to be significantly connected. *CDC37* and *STIP1* encode CDC37 and STI1, respectively, two of several auxiliary proteins that associate with the heat-shock protein 90 (HSP90) molecular chaperone and thus are collectively referred to as HSP90 cochaperones.⁵⁴ HSP90 itself is an abundant, evolutionarily conserved molecular chaperone that acts mainly as a cofactor for the folding of polyproteins into functional, stable, mature proteins, and it physically associates with JAK1 and probably JAK2,⁵⁵ demonstrating that JAK1/2 are client proteins of HSP90. A study in mice and in patient samples suggested that HSP90 inhibitors might help treat

JAK2-dependent myeloproliferative neoplasms (MPNs).⁵⁶ Moreover, inhibition of HSP90 was found to block Nod2-mediated activation of the transcription factor NF- κ B and reduce NALP3-mediated gout-like inflammation in mice,⁵⁷ and mutations in the gene encoding NALP3, a member of the Nod-like receptor (NLR) protein family, are associated with several autoinflammatory disorders.^{58,59} Our hypothesis that *CDC37* and *STIP1* are potential joint risk factors for CD and PS is substantiated by an association peak within *CDC37* in our same-effect combined-phenotype analysis of discovery panels A and B ($p_{\text{GWAS}} = 1.61 \times 10^{-3}$ for rs11879191, Figure S6).

It is worth noting that we used a two tier strategy to identify shared disease risk loci: Both approaches turned out to be effective and complementary tools for gaining insights into the postulated shared pathogenesis of CD and PS. Application of only a single strategy would have decreased the number of identified loci. Although the *OVERLAP* approach represents a simple and cost-effective strategy (cross-disease comparison of known risk SNPs), the *COMBINED* approach provides the power to identify shared susceptibility loci even if association signals are heterogeneous between diseases, that is the particular SNP showing the smallest p value at the considered locus, as was the case, for example, for the identified risk locus at *ZMIZ1*. This heterogeneity of most strongly associated SNPs could be due to interactions with other genetic variants or environmental factors, to differences in the distribution or effect size of causal alleles, or to the fact the identified SNPs show an association signal only because they are in LD with the actual causal variant. In particular, the increase of power due to increased sample sizes makes the *COMBINED* approach a potentially powerful tool to detect shared risk loci that might be missed in disease-specific GWASs that are often underpowered because of their comparatively smaller sample sizes.

Because we did not search for loci harboring association signals with different and independent SNPs in terms of LD associated with CD and PS, there is room for improvement. For instance, in a simple rank approach with regard to single-marker association p values, different disease-associated markers for the same locus could be determined when they rank high with regard to their p value in association scans of CD and PS, respectively. This would allow detecting shared susceptibility loci even if association signals are heterogeneous between diseases. An approach to meet the challenge of the heterogeneity of genetic effects of the same markers between different diseases was proposed by Morris et al.⁶⁰ The authors developed a test of association within a multinomial regression framework and demonstrated the improved power of their multinomial regression-based analysis over existing methods.

It is likely that future studies will identify additional shared disease loci for CD and PS by further increasing the sample size of analyzed case-control panels or, for example, by applying the suggested rank approach. Evidence for a shared etiological basis among several auto-

immune and inflammatory diseases is growing. For Crohn disease, for example, Lees and colleagues currently reported that 51 of the known 71 loci overlap with more than 23 distinct diseases, comprising also several nonautoimmune conditions.⁶¹ Given the success of this study, we expect the same for the investigation of further combinations of such diseases for shared risk factors.

Supplemental Data

Supplemental Data include six figures and five tables and can be found with this article online at <http://www.cell.com/AJHG/>.

Acknowledgments

We thank all individuals with psoriasis or CD, their families, control individuals and clinicians for their participation in this project. We thank the WTCCC consortium for the access to the CD case/control data. We acknowledge the cooperation of Genizon Biosciences. We wish to thank Tanja Wesse, Tanja Henke and Susan Ehlers for expert technical help. We acknowledge EGCUT and Estonian Biocentre personnel, especially Ms. M. Hass and Mr. V. Soo. A list of funding sources is included in the Supplemental Data.

Received: October 28, 2011

Revised: January 30, 2012

Accepted: February 16, 2012

Published online: April 5, 2012

Web Resources

The URLs for data presented herein are as follows:

1000 Genomes Project, <http://www.1000genomes.org/>
BEAGLE, <http://faculty.washington.edu/browning/beagle/beagle.html>
dbGaP, <http://www.ncbi.nlm.nih.gov/gap>
EIGENSTRAT, <http://genepath.med.harvard.edu/~reich/Software.htm>
GRAIL, <http://www.broadinstitute.org/mpg/grail/>
Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org>
PLINK, <http://pngu.mgh.harvard.edu/~purcell/plink/>
PopGen Biobank, <http://www.popgen.de>
VIZ-GRAIL, <http://www.broadinstitute.org/mpg/grail/vizgrail.html>

References

1. Bhalerao, J., and Bowcock, A.M. (1998). The genetics of psoriasis: A complex disorder of the skin and immune system. *Hum. Mol. Genet.* 7, 1537–1545.
2. Elder, J.T., Nair, R.P., Guo, S.W., Henseler, T., Christophers, E., and Voorhees, J.J. (1994). The genetics of psoriasis. *Arch. Dermatol.* 130, 216–224.
3. Russell, R.K., and Satsangi, J. (2004). IBD: A family affair. *Best Pract. Res. Clin. Gastroenterol.* 18, 525–539.
4. Griffiths, C.E., and Barker, J.N. (2007). Pathogenesis and clinical features of psoriasis. *Lancet* 370, 263–271.
5. Logan, I., and Bowlus, C.L. (2010). The geoepidemiology of autoimmune intestinal diseases. *Autoimmun. Rev.* 9, A372–A378.
6. Sagoo, G.S., Cork, M.J., Patel, R., and Tazi-Ahnini, R. (2004). Genome-wide studies of psoriasis susceptibility loci: A review. *J. Dermatol. Sci.* 35, 171–179.

7. Najarian, D.J., and Gottlieb, A.B. (2003). Connections between psoriasis and Crohn's disease. *J. Am. Acad. Dermatol.* *48*, 805–821, quiz 822–804.
8. Khor, B., Gardet, A., and Xavier, R.J. (2011). Genetics and pathogenesis of inflammatory bowel disease. *Nature* *474*, 307–317.
9. Yates, V.M., Watkinson, G., and Kelman, A. (1982). Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. *Br. J. Dermatol.* *106*, 323–330.
10. Bernstein, C.N., Wajda, A., and Blanchard, J.F. (2005). The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study. *Gastroenterology* *129*, 827–836.
11. Weng, X., Liu, L., Barcellos, L.F., Allison, J.E., and Herrinton, L.J. (2007). Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern California-managed care organization. *Am. J. Gastroenterol.* *102*, 1429–1435.
12. Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., Brant, S.R., Silverberg, M.S., Taylor, K.D., Barmada, M.M., et al; NIDDK IBD Genetics Consortium; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat. Genet.* *40*, 955–962.
13. Franke, A., McGovern, D.P., Barrett, J.C., Wang, K., Radford-Smith, G.L., Ahmad, T., Lees, C.W., Balschun, T., Lee, J., Roberts, R., et al. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat. Genet.* *42*, 1118–1125.
14. Nair, R.P., Duffin, K.C., Helms, C., Ding, J., Stuart, P.E., Goldgar, D., Gudjonsson, J.E., Li, Y., Tejasvi, T., Feng, B.J., et al; Collaborative Association Study of Psoriasis. (2009). Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. *Nat. Genet.* *41*, 199–204.
15. Ellinghaus, E., Ellinghaus, D., Stuart, P.E., Nair, R.P., Debrus, S., Raelson, J.V., Belouchi, M., Fournier, H., Reinhard, C., Ding, J., et al. (2010). Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. *Nat. Genet.* *42*, 991–995.
16. Strange, A., Capon, F., Spencer, C.C., Knight, J., Weale, M.E., Allen, M.H., Barton, A., Band, G., Bellenguez, C., Bergboer, J.G., et al; Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2. (2010). A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat. Genet.* *42*, 985–990.
17. Sun, L.D., Cheng, H., Wang, Z.X., Zhang, A.P., Wang, P.G., Xu, J.H., Zhu, Q.X., Zhou, H.S., Ellinghaus, E., Zhang, F.R., et al. (2010). Association analyses identify six new psoriasis susceptibility loci in the Chinese population. *Nat. Genet.* *42*, 1005–1009.
18. Stuart, P.E., Nair, R.P., Ellinghaus, E., Ding, J., Tejasvi, T., Gudjonsson, J.E., Li, Y., Weidinger, S., Eberlein, B., Gieger, C., et al. (2010). Genome-wide association analysis identifies three psoriasis susceptibility loci. *Nat. Genet.* *42*, 1000–1004.
19. Hüffmeier, U., Uebe, S., Ekici, A.B., Bowes, J., Giardina, E., Korndowycz, E., Juneblad, K., Apel, M., McManus, R., Ho, P., et al. (2010). Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. *Nat. Genet.* *42*, 996–999.
20. Zhang, X.J., Huang, W., Yang, S., Sun, L.D., Zhang, F.Y., Zhu, Q.X., Zhang, F.R., Zhang, C., Du, W.H., Pu, X.M., et al. (2009). Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. *Nat. Genet.* *41*, 205–210.
21. Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S., Daly, M.J., Steinhardt, A.H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* *314*, 1461–1463.
22. Cargill, M., Schrodi, S.J., Chang, M., Garcia, V.E., Brandon, R., Callis, K.P., Matsunami, N., Ardlie, K.G., Civeello, D., Catanese, J.J., et al. (2007). A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am. J. Hum. Genet.* *80*, 273–290.
23. Nair, R.P., Ruether, A., Stuart, P.E., Jenisch, S., Tejasvi, T., Hiremagalore, R., Schreiber, S., Kabelitz, D., Lim, H.W., Voorhees, J.J., et al. (2008). Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. *J. Invest. Dermatol.* *128*, 1653–1661.
24. Mannon, P.J., Fuss, I.J., Mayer, L., Elson, C.O., Sandborn, W.J., Present, D., Dolin, B., Goodman, N., Groden, C., Hornung, R.L., et al; Anti-IL-12 Crohn's Disease Study Group. (2004). Anti-interleukin-12 antibody for active Crohn's disease. *N. Engl. J. Med.* *351*, 2069–2079.
25. Abraham, C., and Cho, J.H. (2009). IL-23 and autoimmunity: New insights into the pathogenesis of inflammatory bowel disease. *Annu. Rev. Med.* *60*, 97–110.
26. Di Meglio, P., Di Cesare, A., Laggner, U., Chu, C.C., Napolitano, L., Villanova, F., Tosi, I., Capon, F., Trembath, R.C., Peris, K., and Nestle, F.O. (2011). The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. *PLoS ONE* *6*, e17160.
27. Franke, A., Fischer, A., Nothnagel, M., Becker, C., Grabe, N., Till, A., Lu, T., Müller-Quernheim, J., Wittig, M., Hermann, A., et al. (2008). Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. *Gastroenterology* *135*, 1207–1215.
28. Wellcome Trust Case Control Consortium. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* *447*, 661–678.
29. Franke, A., Balschun, T., Karlsen, T.H., Hedderich, J., May, S., Lu, T., Schuldt, D., Nikolaus, S., Rosenstiel, P., Krawczak, M., and Schreiber, S. (2008). Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. *Nat. Genet.* *40*, 713–715.
30. Wang, K., Baldassano, R., Zhang, H., Qu, H.Q., Imielinski, M., Kugathasan, S., Annese, V., Dubinsky, M., Rotter, J.I., Russell, R.K., et al. (2010). Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. *Hum. Mol. Genet.* *19*, 2059–2067.
31. Cotsapas, C., Voight, B.F., Rossin, E., Lage, K., Neale, B.M., Wallace, C., Abecasis, G.R., Barrett, J.C., Behrens, T., Cho, J., et al; FOCIS Network of Consortia. (2011). Pervasive sharing of genetic effects in autoimmune disease. *PLoS Genet.* *7*, e1002254.
32. Imielinski, M., Baldassano, R.N., Griffiths, A., Russell, R.K., Annese, V., Dubinsky, M., Kugathasan, S., Bradfield, J.P., Walters, T.D., Sleiman, P., et al; Western Regional Alliance for Pediatric IBD; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium. (2009). Common variants at five new loci associated with early-onset inflammatory bowel disease. *Nat. Genet.* *41*, 1335–1340.
33. Festen, E.A., Goyette, P., Green, T., Boucher, G., Beauchamp, C., Trynka, G., Dubois, P.C., Lagacé, C., Stokkers, P.C., Hommes, D.W., et al. (2011). A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP,

- and PUS10 as shared risk loci for Crohn's disease and celiac disease. *PLoS Genet.* 7, e1001283.
34. Zhernakova, A., Stahl, E.A., Trynka, G., Raychaudhuri, S., Festen, E.A., Franke, L., Westra, H.J., Fehrmann, R.S., Kurree- man, F.A., Thomson, B., et al. (2011). Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. *PLoS Genet.* 7, e1002004.
 35. Krawczak, M., Nikolaus, S., von Eberstein, H., Croucher, P.J., El Mokhtari, N.E., and Schreiber, S. (2006). PopGen: Population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. *Community Genet.* 9, 55–61.
 36. Wichmann, H.E., Gieger, C., and Illig, T.; MONICA/KORA Study Group. (2005). KORA-gen—resource for population genetics, controls and a broad spectrum of disease phenotypes. *Gesundheitswesen* 67 (Suppl 1), S26–S30.
 37. Weiland, S.K., Björkstén, B., Brunekreef, B., Cookson, W.O., von Mutius, E., and Strachan, D.P.; International Study of Asthma and Allergies in Childhood Phase II Study Group. (2004). Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC II): Rationale and methods. *Eur. Respir. J.* 24, 406–412.
 38. Manolio, T.A., Rodriguez, L.L., Brooks, L., Abecasis, G., Ballinger, D., Daly, M., Donnelly, P., Faraone, S.V., Frazer, K., Gabriel, S., et al; GAIN Collaborative Research Group; Collaborative Association Study of Psoriasis; International Multi-Center ADHD Genetics Project; Molecular Genetics of Schizophrenia Collaboration; Bipolar Genome Study; Major Depression Stage 1 Genomewide Association in Population-Based Samples Study; Genetics of Kidneys in Diabetes (GoKinD) Study. (2007). New models of collaboration in genome-wide association studies: The Genetic Association Information Network. *Nat. Genet.* 39, 1045–1051.
 39. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., and Reich, D. (2006). Principal components analysis corrects for stratification in genome-wide association studies. *Nat. Genet.* 38, 904–909.
 40. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* 81, 559–575.
 41. Browning, B.L., and Browning, S.R. (2009). A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. *Am. J. Hum. Genet.* 84, 210–223.
 42. Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M., Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., Peltonen, L., et al; International HapMap 3 Consortium. (2010). Integrating common and rare genetic variation in diverse human populations. *Nature* 467, 52–58.
 43. Devlin, B., and Roeder, K. (1999). Genomic control for association studies. *Biometrics* 55, 997–1004.
 44. de Bakker, P.I., Ferreira, M.A., Jia, X., Neale, B.M., Raychaudhuri, S., and Voight, B.F. (2008). Practical aspects of imputation-driven meta-analysis of genome-wide association studies. *Hum. Mol. Genet.* 17 (R2), R122–R128.
 45. 1000 Genomes Project Consortium. (2010). A map of human genome variation from population-scale sequencing. *Nature* 467, 1061–1073.
 46. Raychaudhuri, S., Plenge, R.M., Rossin, E.J., Ng, A.C., Purcell, S.M., Sklar, P., Scolnick, E.M., Xavier, R.J., Altshuler, D., and Daly, M.J.; International Schizophrenia Consortium. (2009). Identifying relationships among genomic disease regions: Predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet.* 5, e1000534.
 47. Dixon, A.L., Liang, L., Moffatt, M.F., Chen, W., Heath, S., Wong, K.C., Taylor, J., Burnett, E., Gut, I., Farrall, M., et al. (2007). A genome-wide association study of global gene expression. *Nat. Genet.* 39, 1202–1207.
 48. Li, X., Thyssen, G., Beliakoff, J., and Sun, Z. (2006). The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. *J. Biol. Chem.* 281, 23748–23756.
 49. Carlsson, B., Kindberg, E., Buesa, J., Rydell, G.E., Lidón, M.F., Montava, R., Abu Mallouh, R., Grahn, A., Rodríguez-Díaz, J., Bellido, J., et al. (2009). The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. *PLoS ONE* 4, e5593.
 50. Ikehara, Y., Nishihara, S., Yasutomi, H., Kitamura, T., Matsuo, K., Shimizu, N., Inada, K., Koder, Y., Yamamura, Y., Narimatsu, H., et al. (2001). Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. *Cancer Epidemiol. Biomarkers Prev.* 10, 971–977.
 51. Starr, R., Willson, T.A., Viney, E.M., Murray, L.J., Rayner, J.R., Jenkins, B.J., Gonda, T.J., Alexander, W.S., Metcalf, D., Nicola, N.A., and Hilton, D.J. (1997). A family of cytokine-inducible inhibitors of signalling. *Nature* 387, 917–921.
 52. Yasukawa, H., Sasaki, A., and Yoshimura, A. (2000). Negative regulation of cytokine signaling pathways. *Annu. Rev. Immunol.* 18, 143–164.
 53. Krebs, D.L., and Hilton, D.J. (2000). SOCS: Physiological suppressors of cytokine signaling. *J. Cell Sci.* 113, 2813–2819.
 54. Abbas-Terki, T., Briand, P.A., Donzé, O., and Picard, D. (2002). The Hsp90 co-chaperones Cdc37 and Sti1 interact physically and genetically. *Biol. Chem.* 383, 1335–1342.
 55. Shang, L., and Tomasi, T.B. (2006). The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. *J. Biol. Chem.* 281, 1876–1884.
 56. Marubayashi, S., Koppikar, P., Taldone, T., Abdel-Wahab, O., West, N., Bhagwat, N., Caldas-Lopes, E., Ross, K.N., Gönen, M., Gozman, A., et al. (2010). HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. *J. Clin. Invest.* 120, 3578–3593.
 57. Mayor, A., Martinon, F., De Smedt, T., Pétrilli, V., and Tschopp, J. (2007). A crucial function of SGT1 and HSP90 in inflammatory activity links mammalian and plant innate immune responses. *Nat. Immunol.* 8, 497–503.
 58. Hoffman, H.M., Mueller, J.L., Broide, D.H., Wanderer, A.A., and Kolodner, R.D. (2001). Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat. Genet.* 29, 301–305.
 59. Hawkins, P.N., Lachmann, H.J., Aganna, E., and McDermott, M.F. (2004). Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. *Arthritis Rheum.* 50, 607–612.
 60. Morris, A.P., Lindgren, C.M., Zeggini, E., Timpson, N.J., Frayling, T.M., Hattersley, A.T., and McCarthy, M.I. (2010). A powerful approach to sub-phenotype analysis in population-based genetic association studies. *Genet. Epidemiol.* 34, 335–343.
 61. Lees, C.W., Barrett, J.C., Parkes, M., and Satsangi, J. (2011). New IBD genetics: Common pathways with other diseases. *Gut* 60, 1739–1753.